10.1039/c9ra07760j">
 

Title

A minimal structural variation can overcome tumour resistance of oxaliplatin: The case of 4,5-dehydrogenation of the cyclohexane ring

Document Type

Article

Publication Date

2019

Department/School

Chemistry

Publication Title

RSC Advances

Abstract

A new family of anticancer compounds has been derived from oxaliplatin by inserting a double-bond between carbons 4 and 5 of the 1,2-diaminocyclohexane ring. Testing against a panel of human tumour cell lines including cervical (A431), ovarian (2008), and colon carcinomas (HCT-15 and LoVo), and two oxaliplatin-resistant clones (LoVo OXP and LoVo MDR) has shown that the new compounds have, in general, equal if not better cytotoxic activity and are able to overcome the oxaliplatin-resistance. Moreover, the oxalato derivative induced lipid droplets increase in LoVo OXP cells thus suggesting the involvement of metabolism stress in its mechanism of action.

Link to Published Version

10.1039/c9ra07760j

Share

COinS